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Deregulated expression of histone deacetylases (HDACs) has been implicated in tumorigenesis. Herein, we investigated
class I HDACs expression in bladder urothelial cell carcinoma (BUCC), its prognostic value and biological significance.
Significantly increased transcript levels of all HDACswere found in BUCC compared to 20 normal mucosas, and thesewere
higher in lower grade and stage tumors. Increased HDAC3 levels were associated with improved patient survival. SiRNA
experiments showed decrease cell viability and motility, and increased apoptosis. We concluded that class I HDACs play an
important role in bladder carcinogenesis through deregulation of proliferation, migration and apoptosis, constituting
putative therapeutic targets. © 2013 Wiley Periodicals, Inc.
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INTRODUCTION
Bladder cancer is a global health concern, being the
11th most common cancer in both genders, account-
ing for 386300 new cases and 150200 deaths per year,
occurring mostly in the 7th decade of life [1,2]. The
adjusted incidence is approximately four times higher
in males than in females, although mortality is only
about twice in men compared to women [2]. Among
bladder tumors, urothelial (transitional cell) carcino-
ma (BUCC) is the most frequent histological subtype,
comprising 90% of all cases [3]. Commonly, urothe-
lial carcinomas are divided in two major groups, the
noninvasive or early invasive tumors [confined to the
urothelium (CIS, Ta) or to the lamina propria (T1),
respectively] also known as “superficial BUCC,”
whereas the remainder are deeply invasive (i.e.,
infiltrating the muscularis propria and beyond)
cancers (T2–T4). The noninvasive tumors are more
prevalent, less aggressive, yet with a high rate of
recurrence, while invasive tumors are less common,
but much more clinically aggressive [4,5]. The
histology of infiltrating urothelial carcinomas is
variable, although most pT1 tumors are papillary,
low or high grade, and most T2–T4 carcinomas are
nonpapillary and high grade [6].
BUCC is a very heterogeneous disease and there is
substantial evidence for the existence of two distinct
molecular pathways in bladder carcinogenesis, in
which distinct genetic alterations are responsible for
the formation of noninvasive or invasive urothelial
tumors, resulting in divergent biological and clinical
phenotypes [7–9]. Noninvasive carcinomas typically
arise in the context of hyperplastic urothelium and
harbor oncogene mutations, such as in fibroblast
growth factor receptor 3 (FGFR3), whereas invasive
tumors arise through dysplasia and often display
mutations in tumor suppressor genes, such as
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TP53 [10–12]. At an epigenetic level, these two groups
of tumors are also distinct. Invasive tumors depict
higher levels of aberrantmethylation and upregulation
of many miRNAs, whereas, in contrast, noninvasive
tumors display low levels of aberranthypermethylation
and downregulation of miRNAs [13,14].
Histone posttranslational modifications play a
crucial role in chromatin structure, being acetylation
the most extensively characterized [15]. Histones’
acetylation is a dynamic process controlled by the
antagonistic actions of acetyltransferases (HATs) and
deacetylases (HDACs), which maintain the equilibri-
um of acetyl groups added or removed from lysine
residues, respectively [16]. HDACs are a family of 18
genes, that act as co-repressors promoting chromatin
compaction, which are grouped into four classes
depending on amino acid sequence homology in the
catalytic domain [17]. Class I HDACs consists on
ubiquitously expressed nuclear enzymes, comprising
HDAC1, HDAC2, HDAC3, and HDAC8, which are
implicated in the regulation of cell differentiation,
proliferation, cell-cycle progression, and apopto-
sis [18]. Except for HDAC8, they are found as subunits
of several multiprotein co-repressor complexes and
interact with various transcription factors, being
HDAC1 and HDAC2 present in the same complexes
(Sin3, NuRD, and CoREST) as homo- or heterodimers
[19,20].
Aberrant expression of class I HDACs has been
reported in several human cancers, including colo-
rectal, gastric, and prostate, and some of these studies
have already disclosed their participation in different
cell functions frequently deregulated in tumors [21–
23]. Nevertheless, the role of these enzymes in bladder
carcinogenesis remains elusive. Hence, we aimed to
characterize the expression patterns of each member
of class I HDACs in bladder cancer and evaluate their
prognostic value, through correlation of molecular
findings with standard clinicopathological data.
Moreover, the biological role of altered class I HDACs
was investigated using a BUCC cell line as an in vitro
model.
MATERIALS AND METHODS
Patients and Samples
The 127 BUCC samples selected for this study
correspond to a series of patients diagnosed and
primarily treated with radical cystectomy or trans-
urethral resection, between 1992 and 2011 at Portu-
guese Oncology Institute—Porto, Portugal, of which
fresh frozen tissue samples were available. For control
purposes, 20 morphological normal bladder mucosa
(NB) tissueswere obtained frompatientswith prostate
cancer submitted to radical prostatectomy. All speci-
mens were fresh-frozen at 808C and subsequently
cut in a cryostat for nucleic acid and protein
extraction. From each specimen, fragments were
routinely collected, formalin-fixed, and paraffin-
embedded for routine histopathological examina-
tion, including grade and pathological staging, by an
expert pathologist. Relevant clinical data was collect-
ed from the clinical charts. This study was approved
by the institutional review board (Comissa˜o de E´tica
para a Sau´de).
Real-Time Quantitative PCR (qRT-PCR)
RNA was extracted from tissues and cell lines using
TRIzol1 (Invitrogen, Carlsbad, CA) according to
manufacturer’s instructions. First strand synthesis
was performed using the high-capacity cDNA Reverse
TranscriptionKit fromAppliedBiosystems (FosterCity,
CA). Expression of target genes was quantified using
Taqman probes, acquired as predeveloped assays from
AppliedBiosystems [HDAC1 (Hs02621185_s1),HDAC2
(Hs00231032_m1), HDAC3 (Hs00187320_m1), and
HDAC8 (Hs00218503_m1)] and normalized to the
expressionofHPRT (Hs01003267_m1), ahousekeeping
gene.
Western Blot
Whole cell line protein extraction was performed
using complete RIPA buffer (Santa Cruz Inc., Santa
Cruz, CA) and protein from tissues was extracted
using TRIzol1 Reagent (Invitrogen) according to
manufacturer’s instructions. Protein extract concen-
trations were determined using Qubit1 2.0 Fluorom-
eter (Applied Biosystems). Subsequently, 30mg of
total protein were loaded in each well, and separated
by SDS–PAGE, transferred to nitrocellulose mem-
branes and probed with antibodies against HDAC1
(Sigma-Aldrich, Schnelldorf, Germany, 1:1000),
HDAC2 (Abcam, Cambridge, UK, 1:6000), HDAC3
(Abcam, 1:6000), HDAC8 (Abcam, 1:1000), p21 (BD
PharmingenTM, Franklin Lakes, NJ, 1:500) or the
endogenous control b-actin (Sigma-Aldrich, 1:8000).
Secondary antibodies, conjugated with horseradish
peroxidase, were incubated at a dilution of 1:3000.
Finally, blots were developed using Immun-StarTM
WesternCTM Kit according to manufacturer’s indica-
tions (BioRad, Hercules, CA) and exposed to Amer-
sham Hyperfilm (GE Healthcare, Fairfield, CT).
Relative optical density determinationwas performed
usingQuantityOne1 Software version 4.6.6. (BioRad).
For cell lines, three independent experiments were
performed.
Cell Culture
Four urothelial BUCC cell lines [5637, J82, T24,
TCCSUP (ATCC—American Type Culture Collection,
Rockville,MD,USA)] were grown in order to select the
most suitable for in vitro studies. All BUCC cell lines
were cultured in the recommended medium, supple-
mented with 10% fetal bovine serum (FBS) (GIBCO1,
Invitrogen) and 1% penicillin–streptomycin (P-S)
(GIBCO1, Invitrogen) at 378C in a humidified
atmosphere containing 5% CO2, and were tested for
Mycoplasma spp. contamination (PCR Mycoplasma
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Detection Set, Clontech Laboratories, Oxford, UK).
After expression analysis for of each class IHDACs, the
5637 cell line was chosen for further studies (data not
shown).
Transient Transfection
Onedayprior to transfection, 5637 cellswere seeded
under standard conditions in 6-well and 96-well flat-
bottomed culture plates in order to reach 30–50%
confluence. Two sets of double-stranded small inter-
ference RNA (siRNA) for HDAC1, 2, 3, and 8 and the
silencer-negative siRNA as a control were purchased
from Eurofins MWG (Ebersberg, Germany), purified
and desalted. The sense strands of the HDAC siRNA
sequences utilized were as follows: HDAC1, AAGCA-
GAUGCAGAGAUUCAAC and CUGUACAUUGACAU
UGAUA; HDAC2, AACAGACGUUAAGGAAGAA and
GGAUUACAUCAUGCUAAGA; HDAC3, GGCACC-
CAAUGAGUUCUAU and GGCUUCACCAAGAGU-
CUUA; HDAC8, CAUUCAGGAUGGCAUACAA and
GUCCCGAGUAUGUCAGUAU.Cellswere transfected
with siRNA (100nM) using Oligofectamine (Invitro-
gen), as indicated by the manufacturer. Cells were
then collected for further investigation 72h after
transfection. Silencing was validated by qRT-PCR and
Western blot.
Viability Assay
Cell viability of 5637 cells following 24-, 48-, and
72-h treatment with class I HDACs siRNAs, performed
in 96-well flat-bottomed culture plates at 12 000 cells
per well, was evaluated by incorporation of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bro-
mide (MTT) (Sigma-Aldrich). The absorbance was
measured using a microplate reader (FLUOstar Ome-
ga, BMG Labtech, Offenburg, Germany) at a wave-
length of 540nm with background subtraction at
630nm. Three replicates were performed for each
condition, using triplicates for each experiment.
Apoptosis Assay
Cell apoptosis was quantified using APO Percentage
apoptosis assay kit (Biocolor Ltd, Belfast, Northern
Ireland) according to themanufacturer’s instructions.
The assay was performed with the same cell con-
ditions of the MTT assay, with apoptotic cells
measured at the end of 72h. The absorbance was
determined using a microplate reader (FLUOstar
Omega, BMG Labtech) at a wavelength of 550nm
with background subtraction at 620nm. Three inde-
pendent experiments were performed, using six
replicates for each experiment.
Wound Healing Assay
Cell migration of 5637 cells was examined using a
monolayer wounding method, after 48 h of trans-
fection, performed in six-well flat-bottomed cul-
ture plates initially seeded with 500 000 cells per
well. The monolayer was wounded by scraping a
line across the well with a sterile pipette tip. Cells
were washed with PBS and refreshed with RPMI
supplemented with 10% fetal bovine serum. After
0, 9, and 24 h, the cultured cells were observed
under a phase-contrast microscope (Olympus IX51,
Olympus, UK) and photographed at marked
spots. Three replicates were performed for each
condition.
Statistical Analysis
Differences in quantitative expression levels be-
tween BUCC and NB were assessed using the
nonparametric Mann–Whitney (M-W) U-test. The
relationship between expression ratios and other
standard clinicopathological variables (gender, tumor
stage, and grade) were determined using the M-W or
Kruskall–Wallis (K-W) tests, as appropriate. A Spear-
man nonparametric correlation test was additionally
performed to compare age and expression levels. The
results of all functional in vitro assays (scramble vs.
silenced cells) were analyzed using one-way analysis
of variance (ANOVA), complemented with a post hoc
Dunnet’s test for multiple comparisons, when
appropriate.
To test the prognostic significance of the expression
status of each class I HDAC, samples were categorized
into two groups based on the respective expression
levels (using the median as the cutoff value). Disease-
specific (DSS) and disease-free survival (DFS) curves
were then constructed for each HDAC using the
Kaplan–Meier method and groups survival were
compared using log-rank test. Since follow-up time
was very heterogeneous, analysis was limited to the
first 5 yr, censoring all times that exceeded that
period. Hazard ratios (HR) were estimated using
univariate Cox regression. A Cox-regression model
comprising all clinicopathological variables and
molecular variables which reached statistical signifi-
cance in univariate analysis (multivariate test) was
also constructed.
All analyses were performed with SPSS software
(SPSS Version 20.0, Chicago, IL) and statistical
significance was set at P<0.05.
RESULTS
Clinical and Pathological Characteristics
Relevant clinical and pathological data were
collected from patient’s clinical charts (Table 1).
All patients and controls were Caucasian. Among
127 tissue samples of bladder carcinoma tested, 100
were from male patients and the remainder from
female patients. All normal mucosas (n¼20) were
collected from males. The majority of cases
(n¼103) corresponded to primary tumors and
only 24 were tumor recurrences. The median age
of the individuals with BUCC was significantly
higher than those of controls (Mann–Whitney,
P¼0.001).
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Expression Patterns of Class I HDACs in Bladder Tissue and
Correlation With the Clinicopathological Parameters
A statistically significant overexpressionof all class I
HDACs was observed in bladder tumors compared to
normal mucosas (Mann–Whitney, P<0.0001 for all,
Figure 1A). Protein expression was determined in
three randomly selected tumor samples and all
displayed higher levels of class I HDACs compared
to normal bladder mucosas (Figure 1B), corroborating
the results obtained for HDACs transcript levels.
Concerning pathological stage and grade, statisti-
cally significant differences were observed only for
HDAC1 and HDAC3 (P<0.001, K-W). Pairwise com-
parisons (NB vs. BUCC; superficial BUCC vs. deeply
invasive, and NB vs. low-grade papillary, high-grade
papillary or invasive; low-grade papillary vs. high-
grade papillary or invasive; high-grade papillary vs.
invasive) were also statistically significant (M-W).
HDAC1 and HDAC3 were downregulated in deeply
invasive and advanced tumors (T2–T4 stages), in
comparison to noninvasive and less advanced carci-
nomas, respectively. Nonetheless, no significant
differences were apparent between low-grade papil-
lary and high-grade papillary tumors (Figure 2).
Regarding HDAC2 and HDAC8, no differences in
transcript levels were found among the different
pathological grades and stages. Moreover, no signifi-
cant association was found between class I HDAC
transcript levels and gender (M-W, P>0.05) or age
(Spearman’s correlation, P>0.05).
Class I HDACs Expression and Patient Survival
Patients with higher levels of HDAC3 had a
significantly better disease-specific survival (HR
¼0.40; 95% CI: 0.17–0.96; P¼0.035), but not
DFS, compared to patients with lower transcript levels
(Figure 3A). As expected, lower grade and lower
pathological stagewere also associatedwith improved
DSS (HR¼8.95; 95% CI: 3.81–21.01; P<0.001 and
HR¼8.12; 95% CI: 3.54–18.63; P<0.001, respective-
ly) (Figure 3B and C). Conversely, HDAC1, HDAC2,
and HDAC8 did not disclose any prognostic value
(either in DSS or DFS) in our dataset. In multivariate
analysis, however, no statistically significance was
found for any of the molecular variables (P>0.05, for
all), although tumor stage disclosed independent
prognostic value for DSS (P¼0.022), but only in
papillary tumors.
Impact of Class I HDACs Silencing on 5637 Cell Line
Phenotype
Quantitative RT-PCR for HDAC1, HDAC2, HDAC3,
and HDAC8 was performed in several BUCC cell lines
(TCCSUP, 5637, T24, and J82). Among all the cell lines
Table 1. Clinical and Histopathological Features of Patients
With Bladder Urothelial Cell Carcinoma (BUCC) and Normal
Bladder Mucosa (NB) Donors
Clinicopathological features BUCC NB
Median age, yrs (range) 72
(35–92)
61
(51–75)
Gender, n (%)
Male 100 (79) 20 (100)
Female 27 (21) 0 (0)
Histopathological grade, n (%)
Papillary carcinoma, low grade 48 (38) n.a.
Papillary carcinoma, high grade 47 (37) n.a.
Invasive carcinoma 28 (22) n.a.
Pathological stage, n (%)
Ta 40 (31) n.a.
T1 53 (42) n.a
T2 23 (18) n.a
T3 3 (2) n.a
T4 4 (3) n.a
n.a., not applicable.
Figure 1. Transcriptional and translational status of class I HDACs expression in BUCC. (A) Distribution ofHDAC1,
HDAC2, HDAC3, and HDAC8 transcript expression levels in bladder tissues [NB (n¼ 20) and BUCC (n¼ 127)]
(P< 0.0001). The represented scale is logarithmic. (B) Protein gel blot analysis of BUCC and NB tissues for class I
HDACs. Blots were incubated with a specific antibody recognizing HDAC1, HDAC2, HDAC3, and HDAC8. Their
expression was corrected to the constitutive protein, b-actin.
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Figure 2. Differential expression of class I HDACs in comparison to clinicopathological variables. (A) Distribution of
HDAC1 and HDAC3 transcript expression levels in bladder tissues according to their pathological stage. (B)
Distribution of HDAC1 and HDAC3 transcript expression levels in bladder tissues according to their pathological
grade. P< 0.0001; P< 0.001; P< 0.01; P< 0.05. The represented scale is logarithmic.
Figure 3. Representative disease-specific survival curves according to HDAC3 expression (A), histopathological
grade (B), and tumor stage (C). Differences in survival were calculated using the log-rank test.
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analyzed, 5637 showed the higher transcript levels
for all HDACs (Supplementary Figure 1) and was,
therefore, selected for phenotypic (cell viability,
apoptotic, and migration capability) assays following
HDAC silencing.
Silencing was successfully accomplished for all
class I HDACs, both at mRNA and protein expres-
sion levels (Figure 4 and Supplementary Figure 2).
An effective reduction in viability was observed
following silencing of each class I HDAC (Dunnet’s
test, P<0.001, Figure 5A). Interestingly, decreased
viability was associated with increased levels of p21,
a well-known proliferation inhibitor (Supplemen-
tary Figure 3). Moreover, significant increased levels
of apoptotic cells were apparent at day 3 for all
silenced HDACs (Dunnet’s test, P<0.001, Figure
5B). Likewise, the number of migrating cells was
significantly decreased, but only for HDAC2 and
HDAC3-silenced cells (Dunnet’s test, P<0.001,
Figure 5C). Interestingly, HDAC1 protein levels
displayed a significant increase after downregula-
tion of HDAC2 (Figure 4).
DISCUSSION
Increasing evidence has emerged over the last years
implicating gene deregulation through the action of
HDACs in cancer initiation and progression [24,25].
Recently, emphasis has been placed on the expression
of specific HDAC isoforms as a few studies reported
aberrant expression of HDAC family members in
several tumors, some of which have already been
demonstrated to participate in different cell func-
tions, whose deregulation is known to lead to
neoplastic transformation [26–31]. Reported data
are, however, conflicting because overexpression of
a specific HDAC has been associated either with a
favorable or a poor prognosis depending on the
considered cancermodel [31]. Thus, the precise role of
class I HDACs deregulation in cancer, and in bladder
carcinogenesis in particular, as well as its putative
prognostic value remain elusive.
To determine whether class I HDACs deregulation
might be implicated in bladder carcinogenesis, we
firstly evaluated HDAC1, HDAC2, HDAC3, and
HDAC8 expression in a large set of human BUCC
tissues. Overall, mRNA and protein levels of all class I
HDACs were upregulated in bladder tumors com-
pared to normal bladder mucosa. These results are in
accordance with previous findings in other carcino-
mas, including colorectal, gastric, and prostatic
carcinomas [21–23]. Concerning HDAC1, our results
also corroborate a previous report, in which mRNA
expression was also found to be increased in a series,
although limited, of urothelial tumors (n¼10) [32].
These findings strongly support an oncogenic role for
class I HDACs in a relatively wide range of common
human neoplasms.
Interestingly,HDAC1 andHDAC3 expression levels
associated, although inversely, with tumor grade and
stage. Indeed, less differentiated and more advanced
tumors displayed lower expression levels of these
HDACs. In other tumor models, however, increased
levels of class I HDACs are associated with a more
aggressive phenotype [21,23,34]. These apparently
contradictory resultsmight be explained based on the
two pathways of bladder oncogenesis. In the light of
this hypothesis, HDAC1 and HDAC3 overexpression
is more pronounced in the superficial urothelial
tumors, characterized by FGFR3, HRAS, and PI3K
mutations [7,33], which carry the better prognosis,
whereas the more clinically aggressive, deeply inva-
sive BUCC display lower expression levels, although
still higher than those of normal urothelium. This is
further supported by our observation that higher
HDAC3 transcript levels significantly associate with
longer DSS, although only in univariate analysis. This
is in line with previous reports on HDAC3 expression
in chronic lymphocytic leukemia [35]. To the best of
Figure 4. Class I HDACs silencing validation. (A) Relative expression ofHDAC1,HDAC2,HDAC3, andHDAC8 in si-
HDAC1, si-HDAC2, si-HDAC3, and si-HDAC8 cells, respectively. Results were normalized to the data obtained with
the Scramble ( represent statistically significant differences of si-HDAC1, si-HDAC2, and si-HDAC1&HDAC2,
comparing to Scramble: P< 0.01; P< 0.001). (B) Protein gel blot analysis of 5637 cell line for HDACs silencing.
Blots were incubated with a specific antibody recognizing HDAC1, HDAC2, HDAC3, and HDAC8. Their expression
was corrected to the constitutive protein, b-actin.
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our knowledge, there is no previously published data
concerning the prognostic value of HDAC3 expres-
sion in BUCC. Hence, our results suggest that class I
HDACs’ upregulation is a common event in bladder
carcinogenesis, occurring in both pathways, although
it seems to play amore important role in the initiation
and progression of superficial tumors, being less
expressive in the deeply invasive tumors. According-
ly, class I HDAC deregulation joins the growing
list of epigenetic alterations, like aberrant DNA
methylation, which are involved in bladder carcino-
genesis [36].
To ascertain the biological role of class I HDACs
deregulation, 5637 BUCC cell line was used as an in
vitro model, for siRNA experiments. Among the four
BUCC cell lines tested, 5637 demonstrated the high-
est transcript levels of all class I HDACs. Owing to that
characteristic and to the fact that this cell line derives
from a grade II bladder carcinoma, mimicking
superficial BUCC lesions, we believe it represents
the ideal model to test the oncogenic role of class I
HDACs in BUCC. Silencing was successfully achieved
for all HDACs, both at mRNA and protein levels,
allowing us to assess the impact on the malignant
phenotype. Remarkably, a significant decrease in cell
viability and increased apoptosis was observed for
each class I HDACs, which is in line with previous
observations in breast [28], colon [22], and lung [37]
cancers. Interestingly, several reports suggested that
HDAC-mediated repression of genes may cause
uncontrolled cell growth, as HDACs repress the
transcription of cyclin-dependent kinase inhibitors
(CDKIs), such as p21 and p57, allowing for continued
proliferation [24,28,38,39]. We were able to confirm
this in our study, as a global increase in p21 expression
was apparent after class I HDACs silencing. Further-
more, we found that the number of migrating cells
was significantly reduced after HDAC2 or HDAC3
silencing. This might be explained by the previously
reported role of class I HDACs in the regulation of
migration-related genes, such as integrins and
MMP2 [40]. Indeed, it has been shown that HDAC3
is involved in altered cell migration in ovarian cancer,
although no significant role for HDAC2 has been
found in the same model [41]. Globally, these results
suggest that overexpression of class I HDACs have an
Figure 5. Impact of class I HDACs silencing in the malignant
phenotype of 5637 cells. (A) Quantification of cell viability by an MTT
assay in Scramble, si-HDAC1, si-HDAC2, si-HDAC3, andHDAC8 cells at
0, 24, 48, and 72 h in culture. (B) Quantification of apoptosis by
APOPercentage assay kit of Scramble, si-HDAC1, si-HDAC2 and si-
HDAC3 and HDAC8 cells at 72 h in culture. Results were normalized to
the data obtained with the Mock. (C) Photographs of the scratch
wound assay after the transfection of HDAC1, HDAC2, HDAC3, and
HDAC8 siRNA. Themigration rate was examined 12 hr after the scratch
and only si-HDAC2 and si-HDAC3 significantly reduced the number of
migrating cells ( represent statistically significant differences of si-
HDACs compared to Scramble: P< 0.05; P 0.001).
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impact on key cellular pathways influencing the
phenotype of malignant urothelial cells. These find-
ings might be of clinical interest because several
HDAC inhibitors have been developed and success-
fully tested as anticancer agents in a wide variety of
solid and hematological malignancies.
Interestingly, in the silencing experiments we
also observed that HDAC1 protein levels increased
after downregulation of HDAC2. However, and in
trend with previous publications, the same effect
was not observed for HDAC1 mRNA lev-
els [38,42,43]. These findings might be explained
by the redundancy and compensatory functions
advocated for those two proteins, according to
specific knockdown and knockout studies [44].
Thus, increased HDAC1 protein levels may be due
to translational or posttranslational changes in
HDAC1 occurring in the absence of HDAC2.
Intriguingly, a similar effect in HDAC2 (i.e., alter-
ations in mRNA or protein levels) was not observed
when HDAC1 was silenced, although HDAC1 and
HDAC2 belong to the same co-repressor complex
form. Hypothetically, this might be explained by a
higher enzymatic efficiency of HDAC2 compared to
that of HDAC1. Accordingly, when HDAC1 is
downregulated, no vicariation might be required
by an increase in HDAC2 expression levels. This
hypothesis might also justify the apparently wider
impact of HDAC2 silencing in the malignant
phenotype, as it impairs migration of BUCC cells,
contrarily to HDAC1 silencing.
In conclusion, we showed that all class I HDACs are
aberrantly overexpressed in BUCC tissues and in vitro
functional assays further suggest an oncogenic role of
those HDACs in a human BUCC cell line. Moreover,
higher HDAC3 transcript levels are predictive of
better outcome in BUCC patients, probably as a result
of its association with superficial bladder carcinomas.
These results suggest that class I HDACs play an
important role in bladder carcinogenesis through
deregulation of genes implicated in cell proliferation,
cell migration, and apoptosis. Although in vivo
experiments were not performed (which might
provide additional data to substantiate the observa-
tions on primary tissues and cell lines), the alterations
depicted in HDACs expression might provide a
rationale for future trials investigating the therapeutic
usefulness of HDAC inhibitors, already in clinical use
for some cancers.
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